Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Sign Up to like & getrecommendations! Published in 2022 at "Pancreas"
DOI: 10.1097/mpa.0000000000001985
Abstract: OBJECTIVE The aim of the study was to clarify the association of skeletal muscle mass and the prognosis of unresectable pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine plus nab-paclitaxel (GnP). METHODS We included 124 unresectable… read more here.
Keywords: sarcopenia; unresectable pancreatic; gemcitabine plus; treated gemcitabine ... See more keywords
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e16204
Abstract: e16204Background: NAPOLI-1 (NCT01494506) was a global phase 3 study in pts with mPDAC previously treated with gemcitabine-based therapy that showed a significant improvement in overall survival (OS... read more here.
Keywords: treated gemcitabine; gemcitabine based; mpdac previously; previously treated ... See more keywords